- Home
- STOK vs JFR Comparison
STOK vs JFR Comparison
Compare STOK & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- JFR
- Stock Information
- Founded
- STOK 2014
- JFR 2004
- Country
- STOK United States
- JFR United States
- Employees
- STOK N/A
- JFR N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- STOK Health Care
- JFR Finance
- Exchange
- STOK Nasdaq
- JFR Nasdaq
- Market Cap
- STOK 997.9M
- JFR 1.1B
- IPO Year
- STOK 2019
- JFR N/A
- Fundamental
- Price
- STOK $19.76
- JFR $8.45
- Analyst Decision
- STOK Strong Buy
- JFR
- Analyst Count
- STOK 6
- JFR 0
- Target Price
- STOK $26.60
- JFR N/A
- AVG Volume (30 Days)
- STOK 920.7K
- JFR 621.7K
- Earning Date
- STOK 08-12-2025
- JFR 01-01-0001
- Dividend Yield
- STOK N/A
- JFR 11.31%
- EPS Growth
- STOK N/A
- JFR N/A
- EPS
- STOK 0.91
- JFR N/A
- Revenue
- STOK $199,893,000.00
- JFR N/A
- Revenue This Year
- STOK $415.58
- JFR N/A
- Revenue Next Year
- STOK N/A
- JFR N/A
- P/E Ratio
- STOK $21.55
- JFR N/A
- Revenue Growth
- STOK 1218.82
- JFR N/A
- 52 Week Low
- STOK $5.35
- JFR $7.61
- 52 Week High
- STOK $20.00
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- STOK 78.62
- JFR 50.68
- Support Level
- STOK $19.07
- JFR $8.39
- Resistance Level
- STOK $19.91
- JFR $8.53
- Average True Range (ATR)
- STOK 1.26
- JFR 0.05
- MACD
- STOK 0.14
- JFR -0.00
- Stochastic Oscillator
- STOK 96.55
- JFR 55.56
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.